Mitigating microtubule toxicity involves careful dose management and monitoring of patients undergoing treatment with microtubule-targeting agents. Advances in nanotechnology and drug delivery systems also hold promise for reducing systemic toxicity by targeting these agents more precisely to cancer cells while sparing healthy tissue.
